Catalyst Event
Celltrion Inc (068270) · Other
From Akros K-Manufacturing 50 Index (AKMNF50)
6/18/2026, 12:00:00 AM
Celltrion disclosed on 2026-06-18 that the approval for Part 1 of the European Phase 3 clinical trial for Remsima SC has expired. A price impact of >=1% is estimated due to the clinical development adjustment.
Korean Translation
2026년 6월 18일, 소아 크론병 대상 램시마SC 유럽 임상 3상 Part 1 승인이 전략 변경으로 만료되었음을 공시함. 임상 전략 수정에 따라 1% 내외의 주가 영향이 예상됨.
Related Recent Events
LG Innotek Co Ltd (011070) · Earnings Release
LG Innotek's Q2 2026 earnings release, for which analysts forecast an earnings surprise with operating profit potentially exceeding KRW 200 billion, is expected.
8/19/2026, 12:00:00 AM
Rainbow Robotics Co Ltd (277810) · Earnings Release
Q2 2026 earnings release scheduled.
8/19/2026, 12:00:00 AM
Isupetasys Co Ltd (007660) · Earnings Release
High price impact expected based on previous earnings surprises; Q2 2026 earnings release scheduled.
8/18/2026, 12:00:00 AM
Simmtech Co Ltd (222800) · Earnings Release
Q2 2026 earnings release scheduled; high impact expected
8/7/2026, 12:00:00 AM
L & F Co (066970) · Earnings Release
Low importance is estimated as the schedule announcement typically has minimal immediate price impact; Q2 2026 earnings release is scheduled.
8/7/2026, 12:00:00 AM
Hanwha Engine Co Ltd (082740) · Earnings Release
Q2 2026 earnings release scheduled.
8/7/2026, 12:00:00 AM